Avalo Therapeutics (AVTX) Gains from Investment Securities (2014 - 2026)
Avalo Therapeutics posted quarterly Gains from Investment Securities of $779000.0 for Q1 2026, up 102.16% on a QoQ basis from -$36.0 million in Q3 2024.
Avalo Therapeutics (AVTX) has 10 years of Gains from Investment Securities data on file, last reported at $779000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities changed N/A year-over-year to $779000.0; the trailing twelve-month figure through Mar 2026 stood at $779000.0 (up 100.53% YoY), and the FY2025 full-year result was $510000.0, changed N/A from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $779000.0, up from -$36.0 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $1.7 billion in Q4 2022 and bottomed at -$112.0 million in Q2 2024.
- The 3-year median for Gains from Investment Securities is $779000.0 (2026), against an average of $326.4 million.
- Peak annual rise in Gains from Investment Securities reached 170100.0% in 2022, while the deepest fall reached 170100.0% in 2022.
- A 3-year view of Gains from Investment Securities shows it stood at $1.7 billion in 2022, then plunged by 102.12% to -$36.0 million in 2024, then jumped by 102.16% to $779000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $779000.0 (Q1 2026), -$36.0 million (Q3 2024), and -$112.0 million (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 779,000.00 |
| Mar 31, 2026 | 779,000.00 |
| Sep 30, 2024 | -36.03 Mn |
| Sep 30, 2024 | -36.03 Mn |
| Jun 30, 2024 | -112.05 Mn |
| Jun 30, 2024 | -112.05 Mn |
| Mar 31, 2024 | 79.28 Mn |
| Mar 31, 2024 | 79.28 Mn |
| Dec 31, 2022 | 1.70 Bn |
| Dec 31, 2022 | 1.70 Bn |
| Dec 31, 2021 | -1.00 Mn |
| Dec 31, 2021 | -1.00 Mn |
| Sep 30, 2021 | 2.00 Mn |
| Sep 30, 2021 | 2.00 Mn |
| Dec 31, 2020 | -376,000.00 |
| Dec 31, 2020 | -376,000.00 |
| Jun 30, 2020 | 376,000.00 |
| Jun 30, 2020 | 376,000.00 |
| Dec 31, 2019 | -1.00 |
| Dec 31, 2019 | -1.00 |
| Sep 30, 2019 | -197,220.00 |
| Sep 30, 2019 | -197,220.00 |
| Jun 30, 2019 | -992,350.00 |
| Jun 30, 2019 | -992,350.00 |
| Mar 31, 2019 | 180,402.00 |
| Mar 31, 2019 | 180,402.00 |
| Dec 31, 2018 | -302,484.00 |
| Dec 31, 2018 | -302,484.00 |
| Sep 30, 2018 | 84,842.00 |
| Sep 30, 2018 | 84,842.00 |
| Jun 30, 2018 | 13,239.00 |
| Jun 30, 2018 | 13,239.00 |
| Mar 31, 2018 | 262,769.00 |
| Mar 31, 2018 | 262,769.00 |
| Sep 30, 2016 | 869,253.00 |
| Sep 30, 2016 | 869,253.00 |
| Jun 30, 2016 | 1.52 Mn |
| Jun 30, 2016 | 1.52 Mn |
| Mar 31, 2016 | 1.45 Mn |
| Mar 31, 2016 | 1.45 Mn |
| Dec 31, 2015 | 959,188.00 |
| Dec 31, 2015 | 959,188.00 |
| Sep 30, 2015 | 72,856.00 |
| Sep 30, 2015 | 72,856.00 |
| Dec 31, 2014 | 6,427.00 |
| Dec 31, 2014 | 6,427.00 |